查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654165

粪钙卫蛋白检测市场规模、份额、趋势分析报告：按分析、最终用途、地区和细分市场预测，2025-2030 年

Fecal Calprotectin Test Market Size, Share & Trends Analysis Report By Assay (Enzyme-linked Immunosorbent, Enzyme Fluroimmunoassay, Quantitative Immunochromatography), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

粪便钙卫蛋白检测市场的成长与趋势

根据 Grand View Research, Inc. 的一份新报告，全球粪便钙卫蛋白检测市场规模预计到 2030 年将达到 95.5 亿美元，2025-2030 年期间的复合年增长率为 11.2%。

大肠直肠癌是全球最常见的癌症之一，其发生率的增加是推动市场成长的主要因素。随着医疗保健系统继续优先考虑早期检测以改善患者的治疗效果并降低医疗保健成本，粪钙卫蛋白检测已成为识别消化道发炎的重要工具，可作为大肠癌的早期指标。该测试测量粪便检体中的钙卫蛋白水平，为医疗专业人员提供有价值的信息，以确定是否需要进行大肠镜检查等进一步的诊断检查。这种非侵入性方法比传统诊断方法具有显着优势，使其成为患者和医疗保健提供者的首选。

推动粪钙卫蛋白检测市场成长的另一个关键因素是发炎性肠道疾病（包括克隆氏症和溃疡性大肠炎）的盛行率不断上升。这些慢性疾病会导致消化道炎症，需要持续监测和管理。粪钙卫蛋白检测在评估 IBD 患者的疾病活动性和监测治疗反应中起着重要作用。随着全球 IBD 盛行率的上升，对粪钙卫蛋白检测等可靠的非侵入性诊断工具的需求预计将会增加，尤其是在已开发国家。无需侵入性手术即可监测病情进展或復发，这是推动医疗保健提供者和患者采用该测试的关键优势。

对预防性医疗保健重要性的认识不断提高也是推动市场发展的关键因素。政府、医疗和倡导团体越来越重视大肠直肠癌和其他消化系统疾病的早期发现。许多国家都实施了结直肠癌国家筛检计划，粪便钙卫蛋白检测通常作为这些计划的一部分。随着越来越多的人接受定期筛检，对粪便钙卫蛋白检测的需求预计会增加。此外，随着大众越来越意识到大肠直肠癌和 IBD 相关风险，对能够在早期检测这些疾病的诊断测试的需求不断增加，从而进一步推动市场成长。

粪便钙卫蛋白检测技术的进步也促进了市场的扩张。随着更准确、更快速、更用户友好的检测设备的发展，粪钙卫蛋白检测变得更加便捷和高效。自动分析仪和家庭检测套组等技术创新使得医疗保健提供者和患者更容易使用这种诊断工具。特别是自动化系统简化了测试流程，提高了临床实验室的吞吐量并提高了测试效率。另一方面，家用检测套组为患者提供了一种方便的方式，让他们可以在舒适的家中监测自己的胃肠道健康。这些进展正在推动粪便钙卫蛋白检测的广泛应用，特别是在医疗保健有限且患者更喜欢独立管理健康的地区。

市场的主要参与企业正专注于技术进步，例如开发易于使用的自动化系统，以简化测试流程并提高临床护理点的处理能力。此外，家庭检测解决方案的趋势日益增长，像 BIOHIT Medical 这样的公司推出了自我检测套组，让患者可以远端监控自己的病情。随着企业寻求扩大产品系列併加强其市场影响力，伙伴关係、联盟和收购也在增加。在日益拥挤的市场中，各公司不断努力使其产品与众不同，竞争策略在很大程度上受到提高测试灵敏度、降低成本和增加患者便利性的需求的影响。

粪便钙卫蛋白检测市场报告重点

  • 根据检测方法，酵素结合免疫吸附测定法在 2024 年占据最大的收入份额，为 66.4%。其优越性的关键原因之一是其在准确检测与发炎性肠道疾病肠道疾病（IBD）和大肠癌等胃肠道疾病相关的发炎方面具有高灵敏度和特异性。
  • 根据应用，发炎性肠道疾病将占据市场主导地位，到 2024 年将占据 66.0% 的最大份额。这是因为它在已开发国家和新兴国家中都越来越流行。
  • 根据最终用途，医院和诊所占比最大，到 2024 年将达到 54.7%。这一领域占据主导地位，是因为医院中接受检测的患者数量庞大。
  • 由于拥有大量主要市场参与企业，北美在全球市场占据主导地位。北美是肠躁症 (IBS) 和其他胃病的发生率较高的地区。此外，该地区完善的医疗基础设施也有助于市场的发展。
  • 由于新兴市场医疗设施的开放，亚太地区预计将以最快的速度成长，在 2025-2030 年的预测期内复合年增长率为 12.7%。此外，对预防性定期检查的日益重视也推动了市场的成长。

目录

第一章调查方法与范围

第 2 章执行摘要

3. 粪便钙卫蛋白检测市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 粪便钙卫蛋白检测市场分析工具
    • 产业分析 – 波特五力分析
    • PESTEL 分析

第 4 章粪便钙卫蛋白检测市场分析、估计与趋势分析

  • 2024 年及 2030 年检测市场占有率
  • 细分仪表板
  • 全球粪便钙卫蛋白检测市场前景（依检测方法）
  • 2018-2030 年市场规模、预测及趋势分析
    • 酵素免疫分析法
    • 萤光免疫分析
    • 定量层析法

第 5 章粪便钙卫蛋白检测市场：按应用进行的估计和趋势分析

  • 2024 年和 2030 年应用市场占有率
  • 细分仪表板
  • 全球粪便钙卫蛋白检测市场应用前景
  • 2018-2030 年市场规模、预测及趋势分析
    • 发炎性肠道疾病
    • 大肠直肠癌
    • 其他的

6. 粪便钙卫蛋白检测市场：依最终用途的估计和趋势分析

  • 2024 年及 2030 年终端用途市场占有率
  • 细分仪表板
  • 全球粪便钙卫蛋白检测市场前景（依最终用途）
  • 2018-2030 年市场规模、预测及趋势分析
    • 医院和诊所
    • 诊断实验室
    • 学术研究所

7. 粪便钙卫蛋白检测市场：区域、估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030 年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • 2024 年主要企业的市场占有率分析
    • Epitope Diagnostics Inc.
    • Hycult BIoTech
    • Actim
    • Eagle Biosciences, Inc.
    • OPERON
    • Svar Life Science
    • BUHLMANN
    • DRG International Inc.
    • ALPCO
    • Diazyme Laboratories
Product Code: GVR-4-68040-500-1

Fecal Calprotectin Test Market Growth & Trends:

The global fecal calprotectin test market size is expected to reach USD 9.55 billion by 2030, registering a CAGR of 11.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of colorectal cancer, which has become one of the most common forms of cancer worldwide, is the major factor for the market growth. As healthcare systems continue to prioritize early detection to improve patient outcomes and reduce healthcare costs, fecal calprotectin testing has emerged as an essential tool for identifying inflammation in the gastrointestinal tract, which can be an early indicator of colorectal cancer. The test, which measures the concentration of calprotectin in stool samples, provides healthcare professionals with valuable information to determine whether further diagnostic procedures, such as colonoscopies, are necessary. This non-invasive approach offers a significant advantage over traditional diagnostic methods, making it a preferred option for both patients and healthcare providers.

Another significant factor contributing to the growth of the fecal calprotectin test market is the increasing prevalence of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. These chronic conditions, which cause inflammation in the digestive tract, require ongoing monitoring and management. Fecal calprotectin tests plays a crucial role in assessing disease activity and monitoring treatment response in patients with IBD. As the global incidence of IBD rises, particularly in developed countries, the demand for reliable, non-invasive diagnostic tools like fecal calprotectin tests is expected to increase. The ability to monitor disease progression and flare-ups without the need for invasive procedures is a key advantage that is driving the adoption of this test among healthcare providers and patients.

The growing awareness of the importance of preventive healthcare is also a significant factor driving the market. Governments, healthcare organizations, and advocacy groups are increasingly focusing on the early detection of colorectal cancer and other gastrointestinal disorders. National screening programs for colorectal cancer are being implemented in many countries, and fecal calprotectin tests are often included as part of these programs. As more individuals undergo routine screening, the demand for fecal calprotectin test is expected to rise. Additionally, as the general population becomes more aware of the risks associated with colorectal cancer and IBD, there is a growing demand for diagnostic tests that can detect these conditions early, further fueling market growth.

Technological advancements in fecal calprotectin test is also contributing to the market's expansion. The development of more accurate, faster, and user-friendly testing devices has made fecal calprotectin tests more accessible and efficient. Innovations such as automated analyzers and home testing kits have made it easier for both healthcare providers and patients to use this diagnostic tool. Automated systems, in particular, have streamlined the testing process, allowing for higher throughput in clinical laboratories and improving the efficiency of testing. Home test kits, on the other hand, provide patients with a convenient way to monitor their gastrointestinal health in the comfort of their own homes. These advancements are helping to drive the adoption of fecal calprotectin tests, particularly in regions where healthcare access may be limited or where patients prefer to manage their health independently.

Key players in the market are focusing on technological advancements, such as the development of user-friendly, automated systems that streamline the testing process and improve throughput in clinical settings. Additionally, there is a growing trend toward home-based testing solutions, with companies like BIOHIT Healthcare introducing self-test kits that allow patients to monitor their condition remotely. The market is also witnessing an increase in partnerships, collaborations, and acquisitions as companies seek to expand their product portfolios and strengthen their market presence. Competitive strategies are heavily influenced by the need to improve test sensitivity, reduce costs, and enhance patient convenience, with companies continuously working to differentiate their products in an increasingly crowded market.

Fecal Calprotectin Test Market Report Highlights:

  • Based on assay, enzyme-linked immunosorbent assay accounted for the largest revenue share of 66.4% in 2024. One of the primary reasons for its dominance is its high sensitivity and specificity, which allows for accurate detection of inflammation associated with gastrointestinal disorders such as inflammatory bowel diseases (IBD) and colorectal cancer
  • Based on application, inflammatory bowel disease dominated the market and accounted for the largest share of 66.0% in 2024.This can be attributed to the increasing prevalence of the disease in emerging as well as developed nations
  • Based on end-use, the hospitals and clinics segment dominated the end use segments with the largest market share of 54.7% in 2024. The segment dominance is attributed to large patient volumes being tested in hospitals
  • North America dominated the global market due to the presence of a large number of major market players. North America has a high prevalence of IBS and other gastric diseases. Furthermore, well-developed healthcare infrastructure fuels regional market growth
  • Asia Pacific is expected to witness the fastest growth with a CAGR of 12.7% over the forecast period from 2025 to 2030, due to the development of healthcare facilities across emerging markets. Furthermore, increasing focus on preventive routine testing is also supporting the market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Assay
    • 1.2.2. Application
    • 1.2.3. End-use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Assay outlook
    • 2.2.2. Application outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Fecal Calprotectin Test Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Colorectal Cancer and IBD
      • 3.2.1.2. Growing Focus on Preventive Healthcare
      • 3.2.1.3. Growing demand for Non-invasive Testing
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited Awareness in Some Regions
      • 3.2.2.2. High Cost of Testing in Certain Markets
  • 3.3. Fecal Calprotectin Test Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Fecal Calprotectin Test Market: Assay Estimates & Trend Analysis

  • 4.1. Assay Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Fecal Calprotectin Test Market by Assay Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Enzyme-Linked Immunosorbent Assay
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.2. Enzyme Fluroimmunoassay
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Quantitative Immunochromatography
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Fecal Calprotectin Test Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Fecal Calprotectin Test Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Inflammatory Bowel Disease
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 5.4.2. Colorectal Cancer
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Others
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Fecal Calprotectin Test Market: End-Use Estimates & Trend Analysis

  • 6.1. End-Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Fecal Calprotectin Test Market by End-Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals and Clinics
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Diagnostic Laboratories
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Academic and Research Institutes
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Fecal Calprotectin Test Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Target disease prevalence
      • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Target disease prevalence
      • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Target disease prevalence
      • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Target disease prevalence
      • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Target disease prevalence
      • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Target disease prevalence
      • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Target disease prevalence
      • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Target disease prevalence
      • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Target disease prevalence
      • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. Target disease prevalence
      • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Target disease prevalence
      • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Target disease prevalence
      • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Target disease prevalence
      • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company market share analysis, 2024
    • 8.3.2. Epitope Diagnostics Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Hycult Biotech
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Actim
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Eagle Biosciences, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. OPERON
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Svar Life Science
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. BUHLMANN
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. DRG International Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. ALPCO
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Diazyme Laboratories
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives

List of Tables

  • Table. 1 List of Abbreviation
  • Table. 2 North America Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 3 North America Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 4 North America Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 5 North America Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
  • Table. 6 U.S. Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 7 U.S. Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 8 U.S. Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 9 Canada Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 10 Canada Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 11 Canada Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 12 Mexico Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 13 Mexico Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 14 Mexico Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 15 Europe Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 16 Europe Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 17 Europe Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 18 Europe Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
  • Table. 19 Germany Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 20 Germany Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 21 Germany Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 22 UK Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 23 UK Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 24 UK Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 25 France Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 26 France Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 27 France Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 28 Italy Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 29 Italy Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 30 Italy Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 31 Spain Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 32 Spain Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 33 Spain Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 34 Sweden Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 35 Sweden Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 36 Sweden Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 37 Norway Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 38 Norway Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 39 Norway Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 40 Denmark Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 41 Denmark Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 42 Denmark Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 43 Asia Pacific Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 44 Asia Pacific Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 45 Asia Pacific Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 46 Asia Pacific Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
  • Table. 47 China Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 48 China Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 49 China Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 50 Japan Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 51 Japan Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 52 Japan Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 53 India Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 54 India Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 55 India Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 56 Australia Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 57 Australia Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 58 Australia Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 59 Thailand Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 60 Thailand Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 61 Thailand Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 62 South Korea Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 63 South Korea Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 64 South Korea Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 65 Latin America Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 66 Latin America Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 67 Latin America Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 68 Latin America Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
  • Table. 69 Brazil Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 70 Brazil Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 71 Brazil Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 72 Argentina Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 73 Argentina Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 74 Argentina Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 75 Middle East and Africa Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 76 Middle East and Africa Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 77 Middle East and Africa Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 78 Middle East and Africa Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
  • Table. 79 South Africa Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 80 South Africa Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 81 South Africa Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 82 Saudi Arabia Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 83 Saudi Arabia Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 84 Saudi Arabia Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 85 UAE Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 86 UAE Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 87 UAE Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 88 Kuwait Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 89 Kuwait Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 90 Kuwait Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Fecal Calprotectin Test: Market outlook
  • Fig. 9 Fecal Calprotectin Test: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Fecal Calprotectin Test Market driver impact
  • Fig. 15 Fecal Calprotectin Test Market restraint impact
  • Fig. 16 Fecal Calprotectin Test Market strategic initiatives analysis
  • Fig. 17 Fecal Calprotectin Test market: Assay movement analysis
  • Fig. 18 Fecal Calprotectin Test market: Assay outlook and key takeaways
  • Fig. 19 Enzyme-Linked Immunosorbent Assay market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Enzyme Fluroimmunoassay market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Quantitative Immunochromatography market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Fecal Calprotectin Test market: Application movement analysis
  • Fig. 23 Fecal Calprotectin Test market: Application outlook and key takeaways
  • Fig. 24 Inflammatory Bowel Disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Fecal Calprotectin Test market: End-Use movement analysis
  • Fig. 28 Fecal Calprotectin Test market: End-Use outlook and key takeaways
  • Fig. 29 Hospitals and Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Diagnostic Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Academic and Research Institutes market estimates and forecasts, 2018 - 2030
  • Fig. 32 Global Fecal Calprotectin Test market: Regional movement analysis
  • Fig. 33 Global Fecal Calprotectin Test market: Regional outlook and key takeaways
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.K. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)